Free Trial

ReposiTrak Inc. (NYSE:TRAK) CEO Randall K. Fields Sells 2,626 Shares

ReposiTrak logo with Computer and Technology background

ReposiTrak Inc. (NYSE:TRAK - Get Free Report) CEO Randall K. Fields sold 2,626 shares of the company's stock in a transaction that occurred on Monday, June 30th. The stock was sold at an average price of $20.01, for a total value of $52,546.26. Following the transaction, the chief executive officer directly owned 159,374 shares in the company, valued at $3,189,073.74. The trade was a 1.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

ReposiTrak Stock Up 3.3%

Shares of TRAK stock traded up $0.64 on Friday, hitting $20.04. 37,722 shares of the stock were exchanged, compared to its average volume of 60,704. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.03 and a current ratio of 6.03. The company has a market capitalization of $366.33 million, a price-to-earnings ratio of 58.94 and a beta of 0.51. ReposiTrak Inc. has a one year low of $15.72 and a one year high of $25.01.

ReposiTrak Cuts Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, August 14th. Stockholders of record on Monday, June 30th will be paid a dividend of $0.0182 per share. The ex-dividend date is Monday, June 30th. This represents a $0.07 annualized dividend and a dividend yield of 0.36%. ReposiTrak's payout ratio is 20.59%.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised ReposiTrak from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd.

Get Our Latest Report on TRAK

Institutional Inflows and Outflows

A hedge fund recently raised its stake in ReposiTrak stock. Ellsworth Advisors LLC boosted its stake in ReposiTrak Inc. (NYSE:TRAK - Free Report) by 10.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,289 shares of the company's stock after purchasing an additional 2,997 shares during the quarter. Ellsworth Advisors LLC owned about 0.17% of ReposiTrak worth $634,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 27.35% of the company's stock.

About ReposiTrak

(Get Free Report)

Park City Group, Inc, a software-as-a-service provider, designs, develops, and markets proprietary software products in North America. The company offers ReposiTrak MarketPlace, a supplier discovery and B2B e-commerce solution; ReposiTrak Compliance and Food Safety solutions, which reduces potential regulatory and legal risk from their supply chain partners; and ReposiTrak Supply Chain solutions that enables customers to manage relationships with suppliers.

Further Reading

Insider Buying and Selling by Quarter for ReposiTrak (NYSE:TRAK)

Should You Invest $1,000 in ReposiTrak Right Now?

Before you consider ReposiTrak, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ReposiTrak wasn't on the list.

While ReposiTrak currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines